ProQR Therapeutics (PRQR) said late Thursday it has filed an application to the European Medicines Agency to start a phase 1 trial of AX-0810 targeting NTCP, a liver cell protein that carries bile acids into cells.
The trial will evaluate safety, tolerability, pharmacokinetics, and target engagement in healthy volunteers, with initial data expected in Q4 2025, the company said.
The shares were rising about 6% in after-hours activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.